Keywords: Sanofi, Zacks Equity Research, Neutral rating

Zacks analysts retain neutral stance on Sanofi

Article | 05 January 2012

Print This

Analysts at USA-based Zacks Equity Research say they are reaffirming their Neutral stance on Sanofi (Euronext: SAN) with a target ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in